- — Brazil officials said the CoronaVac vaccine developed in partnership with Sinovac Biotech Ltd. was 50.38% effective in preventing coronavirus cases, a number that meets the threshold required by global regulators for approval but that’s well below the 78% figure announced last week.
- When very mild cases among the 13,000 volunteers are included, the figure is 50.4% — 167 infected in the placebo arm, and 85 in the vaccine arm.
- The efficacy rate is key for officials to determine how much of the population needs to be immunized in order to halt the spread of the virus.
CoronaVac’s Overall Efficacy in Brazil Measured at 50.4%
